ESMO24: New Standard of Care – Immunotherapy in High-Risk Locally Advanced Cervical Cancer
At ESMO 2024, the 3-year results from the KEYNOTE-A18 study were presented, showing a clinically meaningful benefit of adding immunotherapy to the treatment regimen.